US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

iShares Neuroscience and Healthcare ETF

37.50

+0.16500.44%

Volume:2K

Turnover:66.12K

Market Cap:7.50M

PE:- -

High:37.50

Open:37.46

Low:37.46

Close:37.33

52wk High:43.01

52wk Low:25.42

Shares:200.00K

Float Shares:200.00K

Volume Ratio:0.72

T/O Rate:0.88%

Dividend:0.32

Dividend Rate:0.86%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Dianthus Therapeutics Inc : JP Morgan Initiates Coverage with Overweight Rating; Price Target $135

THOMSON REUTERS

Biohaven Stock is Sinking. Epilepsy Drug Trial Roadblock is Only the Latest Blow.

Alkermes Announces Launch of 9TH Annual Alkermes Pathways Research Awards® Program

THOMSON REUTERS

Structure weakness ‘disconnected’ from underlying data, says Jefferies

Structure Therapeutics reports ACCG-2671, aleniglipron trial results

Scholar Rock Holding Price Target Maintained with a $65.00/Share by HC Wainwright & Co.

Brain-Computer Interface Startups Must Walk the Line Between Vast Potential and Near-Term Medical Reality, Says Formatia Founder

Mizuho survey shows no consensus into Alkermes ADHD data

Dianthus Therapeutics Inc : Citigroup Initiates Coverage with Buy Rating; Target Price $156

THOMSON REUTERS

Alkermes EVP, CLO David Joseph Gaffin Disposes of 2,034 Common Shares Worth $97,651.34

Dianthus EVP, Head of R&D Simrat Randhawa Sells USD 2.45 Million in Common Shares

Praxis Precision Medicines Grants RSUs for 11,535 Shares to 66 New Employees Under 2024 Inducement Plan

Praxis Precision Medicines, Inc. Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dianthus Therapeutics Grants 52,000 Inducement Stock Options at $106.62 Each

Dianthus Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS

Scholar Rock Begins Phase 2 FORGE Trial of Apitegromab in Facioscapulohumeral Muscular Dystrophy

Scholar Rock Says FDA Grants Fast Track Status for Apitegromab in FSHD

Scholar Rock Receives FDA Fast Track Designation for Apitegromab Facioscapulohumeral Muscular Dystrophy (Fshd) Program as Participant Dosing Commences in Phase 2 Forge Trial

THOMSON REUTERS

Alkermes EVP R&D, Chief Medical Officer Craig C. Hopkinson Disposes of 9,000 Shares for $422,874

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/stock/IBRN/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"IBRN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBRN\",,,,,undefined,":{"symbol":"IBRN","market":"US","secType":"STK","nameCN":"iShares Neuroscience and Healthcare ETF","latestPrice":37.495,"timestamp":1789156275774,"preClose":37.33,"halted":0,"volume":1764,"delay":0,"changeRate":0.00442003750334849,"floatShares":200000,"shares":200000,"eps":0,"marketStatus":"Trading","change":0.165,"latestTime":"09-11 15:57:11 EDT","open":37.455,"high":37.5001,"low":37.455,"amount":66124.503144,"amplitude":0.001208,"askPrice":37.53,"askSize":300,"bidPrice":37.27,"bidSize":300,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1789156800000},"marketStatusCode":2,"adr":0,"exchange":"ARCA","adjPreClose":37.33,"sharesOutstanding":150000,"nav":37.987926,"aum":7597585.2,"dividendRate":0.008561,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":37.374,"preClose":37.33,"latestTime":"16:10 EDT","volume":6,"amount":223.98,"timestamp":1789071007633,"change":0.044,"changeRate":0.001179,"amplitude":0},"volumeRatio":0.722944,"impliedVol":0.1203,"impliedVolPercentile":0.6534},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBRN\",,,,,undefined,":{"symbol":"IBRN","floatShares":200000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.722944,"shares":200000,"dividePrice":0.321,"high":37.5001,"amplitude":0.001208,"preClose":37.33,"low":37.455,"week52Low":25.4196,"pbRate":"--","week52High":43.01,"institutionHeld":0,"latestPrice":37.495,"eps":0,"divideRate":0.008561,"volume":1764,"delay":0,"ttmEps":0,"open":37.455,"prevYearClose":32.3193,"prevWeekClose":39.0596,"prevMonthClose":38.9601,"prevQuarterClose":38.8263,"fiveDayClose":39.3744,"twentyDayClose":39.1008,"sixtyDayClose":34.6111},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBRN\",params:#limit:5,,,undefined,":[{"date":"2025-12-16","symbol":"IBRN","amount":0.319807,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"iShares Neuroscience and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-19","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-19"},{"date":"2024-12-17","symbol":"IBRN","amount":0.10114,"announcedDate":"2024-12-16","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-17","defaultRemindTime":1734445800000,"name":"iShares Neuroscience and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-20","payableDate":"2024-12-17","currency":"USD","dateTimestamp":1734411600000,"payDate":"2024-12-20"},{"date":"2023-12-20","symbol":"IBRN","amount":0.006303,"announcedDate":"2023-12-19","type":"dividend","market":"US","newRecordDate":"2023-12-21","defaultRemindTime":1703082600000,"name":"iShares Neuroscience and Healthcare ETF","recordDate":"2023-12-27","payableDate":"2023-12-21","currency":"USD","dateTimestamp":1703048400000,"payDate":"2023-12-27"},{"date":"2023-06-07","symbol":"IBRN","amount":0.008241,"announcedDate":"2023-05-12","type":"dividend","market":"US","newRecordDate":"2023-06-08","defaultRemindTime":1686144600000,"name":"iShares Neuroscience and Healthcare ETF","recordDate":"2023-06-13","payableDate":"2023-06-08","currency":"USD","dateTimestamp":1686110400000,"payDate":"2023-06-13"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBRN\",market:\"US\",,,undefined,":[{"executeDate":"2023-06-07","recordDate":"2023-06-08","paymentDate":"2023-06-13","value":0.008241,"currency":"USD"},{"executeDate":"2023-12-20","recordDate":"2023-12-21","paymentDate":"2023-12-27","value":0.006303,"currency":"USD"},{"executeDate":"2024-12-17","recordDate":"2024-12-17","paymentDate":"2024-12-20","value":0.10114,"currency":"USD"},{"executeDate":"2025-12-16","recordDate":"2025-12-16","paymentDate":"2025-12-19","value":0.319807,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBRN\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBRN\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666254398","title":"Dianthus Therapeutics Inc : JP Morgan Initiates Coverage with Overweight Rating; Price Target $135","url":"https://stock-news.laohu8.com/highlight/detail?id=2666254398","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666254398?lang=en_us&edition=fundamental","pubTime":"2026-09-11 12:34","pubTimestamp":1789101255,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nFWN4520M0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","DNTH","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666590103","title":"Biohaven Stock is Sinking. Epilepsy Drug Trial Roadblock is Only the Latest Blow.","url":"https://stock-news.laohu8.com/highlight/detail?id=2666590103","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666590103?lang=en_us&edition=fundamental","pubTime":"2026-09-11 02:14","pubTimestamp":1789064040,"startTime":"0","endTime":"0","summary":"Biohaven has hit another regulatory hurdle for its epilepsy candidate opakalim, piling fresh uncertainty onto the cash-strapped biotech.Biohaven confirmed Thursday that the Food and Drug Administratio","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IBRN","BHVN","LU1093756325.SGD","XENE","SBIO","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666567022","title":"Alkermes Announces Launch of 9TH Annual Alkermes Pathways Research Awards® Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2666567022","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666567022?lang=en_us&edition=fundamental","pubTime":"2026-09-10 19:00","pubTimestamp":1789038000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nTUA8WKBZB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PSCH","BK4139","MEDX","IBRN","ALKS","FBT","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666377632","title":"Structure weakness ‘disconnected’ from underlying data, says Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2666377632","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666377632?lang=en_us&edition=fundamental","pubTime":"2026-09-09 04:00","pubTimestamp":1788897615,"startTime":"0","endTime":"0","summary":"After Structure Therapeutics (GPCR) reported clinical trial results from its two lead product candidates, ACCG-2671 and aleniglipron, Jefferies see...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/structure-weakness-disconnected-from-underlying-data-says-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/structure-weakness-disconnected-from-underlying-data-says-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IBB","XPH","BME","IDNA","MEDX","WDNA","PJP","BBP","GNOM","FHLC","IBBJ","PBPH","BIB","JDOC","CURE","TBXU","PINK","IEIH","FTXH","MEDI","CANC","LFSC","HYLG","PTH","AZNH","CNCR","GNMX","GPCR","GSKH","IBBQ","PSCH","FXH","APXH","MNTL","MRNY","BBH","PSIL","LLYX","MDTX","NVIB","GDOC","JHMH","HRTS","PBE","RSPH","FBT","SBIO","SYNB","SURI","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665637847","title":"Structure Therapeutics reports ACCG-2671, aleniglipron trial results","url":"https://stock-news.laohu8.com/highlight/detail?id=2665637847","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665637847?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:36","pubTimestamp":1788871007,"startTime":"0","endTime":"0","summary":"Structure Therapeutics (GPCR) reported clinical trial results from its two lead product candidates: ACCG-2671, an oral, non-peptide, small molecule...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/structure-therapeutics-reports-accg-2671-aleniglipron-trial-results-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/structure-therapeutics-reports-accg-2671-aleniglipron-trial-results-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AZNH","MEDI","PBPH","BME","SYNB","JDOC","FXH","GDOC","CNCR","XPH","CURE","HYLG","MEDX","CANC","RSPH","PINK","BBP","TBXU","NVIB","FHLC","GNMX","PSCH","HRTS","IBB","SBIO","IBRN","BIB","FTXH","LFSC","SURI","IDNA","GPCR","GSKH","IBBJ","LENZ","IBBQ","PTH","PJP","JHMH","MDTX","WDNA","LLYX","PSIL","BBH","MNTL","FBT","PBE","MRNY","APXH","GNOM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665322621","title":"Scholar Rock Holding Price Target Maintained with a $65.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2665322621","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665322621?lang=en_us&edition=fundamental","pubTime":"2026-09-08 19:00","pubTimestamp":1788865200,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SRRK/analyst-ratings","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SRRK","THNR","IBRN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121796426","title":"Brain-Computer Interface Startups Must Walk the Line Between Vast Potential and Near-Term Medical Reality, Says Formatia Founder","url":"https://stock-news.laohu8.com/highlight/detail?id=1121796426","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121796426?lang=en_us&edition=fundamental","pubTime":"2026-09-05 14:10","pubTimestamp":1788588618,"startTime":"0","endTime":"0","summary":"At the 2026 Yabuli Forum Summer Annual Meeting, held September 4-6 in Chengdu, Sichuan, under the theme \"Enterprise Innovation and Cycle Crossing,\" Formatia Founder and CEO Peng Lei offered a...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09996","GDOC","IEIH","AGNG","BK1583","MNTL","PTH","MDEV","BK1574","HART","IBRN","RSPH","LNGR","BK1100","159883","MEDX","LGHT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665735956","title":"Mizuho survey shows no consensus into Alkermes ADHD data","url":"https://stock-news.laohu8.com/highlight/detail?id=2665735956","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665735956?lang=en_us&edition=fundamental","pubTime":"2026-09-05 03:35","pubTimestamp":1788550508,"startTime":"0","endTime":"0","summary":"Mizuho conducted a survey of 13 investors ahead of Alkermes (ALKS)’ Phase 1b trial of ALKS-7290 in adult attention-deficit/hyperactivity disorder, ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mizuho-survey-shows-no-consensus-into-alkermes-adhd-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mizuho-survey-shows-no-consensus-into-alkermes-adhd-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL","IBRN","PSCH","ABVC","ADHD","FBT","MEDX","ALKS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664335196","title":"Dianthus Therapeutics Inc : Citigroup Initiates Coverage with Buy Rating; Target Price $156","url":"https://stock-news.laohu8.com/highlight/detail?id=2664335196","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664335196?lang=en_us&edition=fundamental","pubTime":"2026-09-04 18:09","pubTimestamp":1788516590,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260904:nFWN44W0N3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DNTH","IBRN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664802637","title":"Alkermes EVP, CLO David Joseph Gaffin Disposes of 2,034 Common Shares Worth $97,651.34","url":"https://stock-news.laohu8.com/highlight/detail?id=2664802637","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664802637?lang=en_us&edition=fundamental","pubTime":"2026-09-04 06:33","pubTimestamp":1788474793,"startTime":"0","endTime":"0","summary":"Alkermes EVP, CLO David Joseph Gaffin disposes of 2,034 common shares worth $97,651.34Alkermes EVP and chief legal officer David Joseph Gaffin sold 2,034 ordinary shares on Sep. 3, 2026 at USD 48.01.D","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nNDL5DSLJB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Alkermes EVP, CLO David Joseph Gaffin Disposes of 2,034 Common Shares Worth $97,651.34","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSCH","ALKS","MEDX","BK4139","PSIL","FBT","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664236801","title":"Dianthus EVP, Head of R&D Simrat Randhawa Sells USD 2.45 Million in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2664236801","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664236801?lang=en_us&edition=fundamental","pubTime":"2026-09-04 04:31","pubTimestamp":1788467497,"startTime":"0","endTime":"0","summary":"Dianthus EVP, Head of R&D Simrat Randhawa sells USD 2.45 million in common sharesDianthus Therapeutics EVP, Head of R&D Simrat Randhawa reported option exercises, acquiring 23,124 common shares on Sep","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nNDL5wp3sF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Dianthus EVP, Head of R&D Simrat Randhawa Sells USD 2.45 Million in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DNTH","IBRN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664480943","title":"Praxis Precision Medicines Grants RSUs for 11,535 Shares to 66 New Employees Under 2024 Inducement Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2664480943","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664480943?lang=en_us&edition=fundamental","pubTime":"2026-09-04 04:01","pubTimestamp":1788465672,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines grants RSUs for 11,535 shares to 66 new employees under 2024 inducement planPraxis Precision Medicines granted restricted stock units covering 11,535 common shares to 66 new","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nNDLbxsWyw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU0109394709.USD","SG9999014005.SGD","LU2095319765.USD","IE0009355771.USD","IE00BQXX3D17.EUR","IE00B4R5TH58.HKD","IE00B64PRP62.GBP","IE00BQXX3C00.GBP","IE00BGHQF748.EUR","NDAQ","IBRN","IE00BKPKM429.USD","LU0320765992.SGD","PRAX","IE00BN0W2V16.EUR","IE00BFTCPJ56.SGD","BK4588","LU2210150020.SGD","SG9999014039.USD","BK4585","IE00BN0W2W23.USD","IE00BQXX3F31.USD","LU0314104364.USD","IE00B3QW5Z07.USD","SG9999014013.SGD","IE00BN0W2T93.GBP","SG9999014021.USD","IE00B2B36J28.USD","LU0889565916.HKD","LU2210149790.SGD","IE00BJJMRZ35.SGD","BCDF","IE0002141913.USD","BK4139","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664180910","title":"Praxis Precision Medicines, Inc. Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2664180910","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664180910?lang=en_us&edition=fundamental","pubTime":"2026-09-04 04:01","pubTimestamp":1788465660,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nTUAX4T6R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00B4R5TH58.HKD","IBRN","PRAX","IE0009355771.USD","LU0320765992.SGD","BK4139","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","LU0109394709.USD","LU0889565916.HKD","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","IE0002141913.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664580111","title":"Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2664580111","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664580111?lang=en_us&edition=fundamental","pubTime":"2026-09-04 04:01","pubTimestamp":1788465660,"startTime":"0","endTime":"0","summary":"Investor Contact:. 857-702-9452. Media Contact:. Dan Ferry. LifeSci Advisors. 617-430-7576","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/03/3356230/0/en/praxis-precision-medicines-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJT1NW94.SGD","BK4561","IBRN","ASO","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","LU0889565916.HKD","IE00B2B36J28.USD","BK4200","BK4135","IE0009355771.USD","CNS","IE0002141913.USD","LCLG","PRAX","BK4139","IE00B4R5TH58.HKD","LU0320765992.SGD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664841493","title":"Dianthus Therapeutics Grants 52,000 Inducement Stock Options at $106.62 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=2664841493","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664841493?lang=en_us&edition=fundamental","pubTime":"2026-09-03 05:01","pubTimestamp":1788382890,"startTime":"0","endTime":"0","summary":"Dianthus Therapeutics grants 52,000 inducement stock options at $106.62 eachDianthus Therapeutics granted inducement stock options covering 52,000 shares to four newly hired non-executive employees on","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nNDL5qpRwy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","BK4585","IE00BGHQF748.EUR","BK4588","IE00B64PRP62.GBP","LU2210150020.SGD","IBRN","SG9999014039.USD","IE00BKPKM429.USD","BCDF","LU0314104364.USD","IE00BN0W2T93.GBP","IE00BQXX3C00.GBP","IE00BQXX3D17.EUR","BK4139","IE00BQXX3F31.USD","BK4112","DNTH","SG9999014021.USD","NDAQ","SG9999014005.SGD","IE00B3QW5Z07.USD","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","SG9999014013.SGD","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664584117","title":"Dianthus Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2664584117","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664584117?lang=en_us&edition=fundamental","pubTime":"2026-09-03 05:00","pubTimestamp":1788382800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nTUA4MXXGW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IBRN","BK4139","DNTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664819267","title":"Scholar Rock Begins Phase 2 FORGE Trial of Apitegromab in Facioscapulohumeral Muscular Dystrophy","url":"https://stock-news.laohu8.com/highlight/detail?id=2664819267","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664819267?lang=en_us&edition=fundamental","pubTime":"2026-09-02 20:02","pubTimestamp":1788350571,"startTime":"0","endTime":"0","summary":"Scholar Rock begins Phase 2 FORGE trial of apitegromab in facioscapulohumeral muscular dystrophyScholar Rock received FDA Fast Track designation for apitegromab in facioscapulohumeral muscular dystrop","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nNDL6SFC9d:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["THNR","BK4139","SRRK","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664194998","title":"Scholar Rock Says FDA Grants Fast Track Status for Apitegromab in FSHD","url":"https://stock-news.laohu8.com/highlight/detail?id=2664194998","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664194998?lang=en_us&edition=fundamental","pubTime":"2026-09-02 20:01","pubTimestamp":1788350483,"startTime":"0","endTime":"0","summary":"Scholar Rock says FDA grants fast track status for apitegromab in FSHDFDA granted Fast Track designation for apitegromab in facioscapulohumeral muscular dystrophy, adding to Orphan Drug status for the","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nNDL6lMHWJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["THNR","IBRN","BK4139","SRRK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664139819","title":"Scholar Rock Receives FDA Fast Track Designation for Apitegromab Facioscapulohumeral Muscular Dystrophy (Fshd) Program as Participant Dosing Commences in Phase 2 Forge Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2664139819","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664139819?lang=en_us&edition=fundamental","pubTime":"2026-09-02 20:00","pubTimestamp":1788350402,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nTUA23ZKPQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IBRN","BK4139","SRRK","THNR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664864142","title":"Alkermes EVP R&D, Chief Medical Officer Craig C. Hopkinson Disposes of 9,000 Shares for $422,874","url":"https://stock-news.laohu8.com/highlight/detail?id=2664864142","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664864142?lang=en_us&edition=fundamental","pubTime":"2026-09-02 07:09","pubTimestamp":1788304180,"startTime":"0","endTime":"0","summary":"Alkermes EVP R&D, Chief Medical Officer Craig C. Hopkinson disposes of 9,000 shares for $422,874Craig C. Hopkinson, EVP R&D, Chief Medical Officer, sold 9,000 ordinary shares on Sep. 1 at USD 46.99.He","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nNDLgbNz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Alkermes EVP R&D, Chief Medical Officer Craig C. Hopkinson Disposes of 9,000 Shares for $422,874","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSIL","ALKS","PSCH","BK4139","MEDX","FBT","IBRN"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}]}}